How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia

Blood

Volumn 123, Issue 18, 2014, Pages 2777-2782

  Sanz, Miguel A ^a   Montesinos, Pau ^a,b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ARSENIC TRIOXIDE; BLOOD CLOTTING FACTOR; DEXAMETHASONE; FRESH FROZEN PLASMA; FUROSEMIDE; HYPERTENSIVE AGENT; IDARUBICIN; RETINOIC ACID;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; ASSISTED VENTILATION; BLEEDING TENDENCY; CANCER CHEMOTHERAPY; CANCER PATIENT; CASE REPORT; CORTICOSTEROID THERAPY; CRYOPRECIPITATE; DIFFERENTIATION SYNDROME; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG WITHDRAWAL; DYSPNEA; ECHOCARDIOGRAPHY; EPISTAXIS; FATIGUE; FEMALE; FEVER; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPOTENSION; IMMUNOHISTOCHEMISTRY; INTENSIVE CARE UNIT; KIDNEY FAILURE; LEUKOCYTE COUNT; LUNG HEMORRHAGE; LUNG INFILTRATE; MALE; OXYGEN SATURATION; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PLEURA EFFUSION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROPHYLAXIS; RESPIRATORY DISTRESS; RETINOIC ACID SYNDROME; SKIN BRUISING; THORAX RADIOGRAPHY; THROMBOCYTE TRANSFUSION; WEIGHT GAIN;

ADULT; ARSENICALS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; OXIDES; PREMEDICATION; SYNDROME; TRETINOIN;

EID: 84900463917     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-10-512640     Document Type: Article

References (37)

1. Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP Jr. The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med. 1992;117 (4):292-296.
2. Dubois C, Schlageter MH, de Gentile A, et al. Hematopoietic growth factor expression and ATRA sensitivity in acute promyelocytic blast cells. Blood. 1994;83 (11):3264-3270. (Pubitemid 24158472)
3. Seale J, Delva L, Renesto P, et al. All-trans retinoic acid rapidly decreases cathepsin G synthesis and mRNA expression in acute promyelocytic leukemia. Leukemia. 1996;10 (1): 95-101. (Pubitemid 26052986)
4. Larson RS, Brown DC, Sklar LA. Retinoic acid induces aggregation of the acute promyelocytic leukemia cell line NB-4 by utilization of LFA-1 and ICAM-2. Blood. 1997;90 (7):2747-2756. (Pubitemid 27413485)
5. Marchetti M, Falanga A, Giovanelli S, Oldani E, Barbui T. All-trans-retinoic acid increases adhesion to endothelium of the human promyelocytic leukaemia cell line NB4. Br J Haematol. 1996;93 (2):360-366. (Pubitemid 26150026)
6. Montesinos P, Bergua JM, Vellenga E, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood. 2009;113 (4):775-783.
7. Sanz MA, Martín G, Rayón C, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood. 1999;94 (9):3015-3021. (Pubitemid 29512705)
8. Sanz MA, Martín G, Gonź alez M, et al; Programa de Estudio y Traitmiento de las Hemopatías Malignas. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004;103 (4):1237-1243. (Pubitemid 38168633)
9. Lo-Coco F, Avvisati G, Vignetti M, et al; Italian GIMEMA Cooperative Group. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood. 2010;116 (17):3171-3179.
10. Iland HJ, Bradstock K, Supple SG, et al; Australasian Leukaemia and Lymphoma Group. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 2012;120 (8): 1570-1580, quiz 1752.
11. Lo-Coco F, Avvisati G, Vignetti M, et al; Gruppo Italiano Malattie Ematologiche dell'Adulto; German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance Leukemia. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369 (2):111-121.
12. Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009; 27 (4):504-510.
13. Adès L, Chevret S, Raffoux E, et al; European Acute Promyelocytic Leukemia Group. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol. 2006;24 (36): 5703-5710.
14. Sanz MA, Montesinos P, Rayón C, et al PETHEMA and HOVON Groups. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood. 2010;115 (25): 5137-5146.
15. Rego EM, Kim HT, Ruiz-Argüelles GJ, et al. Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. Blood. 2013;121 (11): 1935-1943.
16. Wiley JS, Firkin FC; Australian Leukaemia Study Group. Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia. Leukemia. 1995;9 (5):774-778.
17. De Botton S, Dombret H, Sanz M, et al; The European APL Group. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. Blood. 1998;92 (8): 2712-2718. (Pubitemid 28469083)
18. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009; 113 (9):1875-1891.
19. de la Serna J, Montesinos P, Vellenga E, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood. 2008;111 (7): 3395-3402.
20. Yanada M, Matsushita T, Asou N, et al. Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome. Eur J Haematol. 2007;78 (3):213-219.
21. Falanga A, Rickles FR. Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia. Best Pract Res Clin Haematol. 2003;16 (3):463-482.
22. Tallman MS, Lefèbvre P, Baine RM, et al. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. J Thromb Haemost. 2004;2 (8):1341-1350. (Pubitemid 40186131)
23. Di Noto R, Schiavone EM, Ferrara F, Manzo C, Lo Pardo C, Del Vecchio L. All-trans retinoic acid promotes a differential regulation of adhesion molecules on acute myeloid leukaemia blast cells. Br J Haematol. 1994;88 (2):247-255. (Pubitemid 24318169)
24. Vahdat L, Maslak P, Miller WH Jr, et al. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood. 1994;84 (11): 3843-3849.
25. Cortes JE, Kantarjian H, O'Brien S, et al. All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia. Cancer. 1994;73 (12): 2946-2952. (Pubitemid 24170767)
26. Avvisati G, Lo Coco F, Diverio D, et al. AIDA (all-trans retinoic acid 1 idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood. 1996; 88 (4):1390-1398. (Pubitemid 26276815)
27. Kanamaru A, Takemoto Y, Tanimoto M, et al; Japan Adult Leukemia Study Group. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Blood. 1995;85 (5): 1202-1206.
28. Fenaux P, Le Deley MC, Castaigne S, et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood. 1993;82 (11):3241-3249. (Pubitemid 23356690)
29. Tallman MS, Andersen JW, Schiffer CA, et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood. 2000;95 (1):90-95. (Pubitemid 30017230)
30. Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood. 1997;90 (3):1014-1021.
31. Jung JI, Choi JE, Hahn ST, Min CK, Kim CC, Park SH. Radiologic features of all-trans-retinoic acid syndrome. AJR Am J Roentgenol. 2002; 178 (2):475-480. (Pubitemid 34098063)
32. Burnett AK, Hills RK, Grimwade D, et al; United Kingdom National Cancer Research Institute Acute Myeloid Leukaemia Subgroup. Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial. Leukemia. 2013;27 (4):843-851.
33. Asou N, Kishimoto Y, Kiyoi H, et al; Japan Adult Leukemia Study Group. A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood. 2007;110 (1):59-66. (Pubitemid 47026819)
34. Lengfelder E, Haferlach C, Saussele S, et al; German AML Cooperative Group. High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG. Leukemia. 2009;23 (12): 2248-2258.
35. Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010;116 (19):3751-3757.
36. Hu J, Liu Y-F, Wu C-F, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA. 2009;106 (9):3342-3347.
37. Mathews V, George B, Chendamarai E, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol. 2010; 28 (24):3866-3871.